Skip to main content
. Author manuscript; available in PMC: 2008 Jan 17.
Published in final edited form as: Arthritis Rheum. 2003 Mar;48(3):737–745. doi: 10.1002/art.10836

Table 2.

CL15-reactive peptides and their modified ones*

Sequence Designation
APVCVWERLSPYRERCV CL151A
APVCVWERLSPYRERCVPAEG CL151E
HWDPFSLSAYFP CL154A
HWDPFSLSAYFPGGGS CL154E
CHWDPFSLSAYFPGGGSC CL154C
*

The carboxyl-termini of peptides CL151 and CL154 were amidated, and the modified peptides were designated CL151A and CL154A, respectively. CL151A and CL154A were modified by adding 4 extra residues to their carboxyl-termini (the added flanking residues are underlined), and the modified peptides were designated CL151E and CL154E (E denotes “extended”), respectively. To improve the stability of peptide CL154E in liquid phase, cysteine (Cys) was added to both ends of CL154E, and this further modification was designated CL154C (C denotes “Cys” and the added Cys are underlined). This was not done for CL151E, since it already had 2 Cys near its N- and C-terminals.